Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 14/20 | 0.43 |
| ▸ | TDO2 | P48775 | 14/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111425 | 0.79 | ALDH1A1 (0.42) | IDO1TDO2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3101008 | 0.77 | IDO1 (0.42) | IDO1TDO2 | |
| SCHEMBL19276929 | 0.73 | IDO1 (0.39) | IDO1TDO2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3105161 | 0.72 | PDE2A (0.45) | IDO1TDO2SMN1; SMN2 | |
| SCHEMBL22150042 | 0.71 | ALOX5 (0.47) | ALDH1A1ALOX5HTR1A | |
| SCHEMBL7326998 | 0.71 | ALOX5 (0.47) | ALDH1A1ALOX5HTR1A | |
| SCHEMBL3089860 | 0.69 | BRD4 (0.41) | IDO1TDO2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3095430 | 0.67 | IDO1 (0.45) | IDO1TDO2DHODH | |
| SCHEMBL3101491 | 0.67 | IDO1 (0.45) | IDO1TDO2 | |
| SCHEMBL16423517 | 0.67 | DHODH (0.37) | IDO1TDO2ALDH1A1HPGDDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | IDO1 1206/4885TDO2 1785/4885ALDH1A1 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.